Published in J Hepatol on November 01, 2003
The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis (2007) 1.02
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis (2004) 0.94
Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol (2007) 0.93
IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol (2008) 0.91
Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One (2013) 0.90
Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol (2006) 0.82
Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World J Gastroenterol (2012) 0.77
IFN-γ-STAT1-iNOS Induces Myeloid Progenitors to Acquire Immunosuppressive Activity. Front Immunol (2017) 0.75
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med (2005) 1.93
Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int (2008) 1.76
Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood (2006) 1.29
Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev (2011) 1.14
The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res (2002) 1.08
Use of TNFα antagonists in refractory AIH: revealing the unforeseen. J Hepatol (2013) 1.07
Intrafamilial spread of hepatitis B virus infection in Greece. Eur J Gastroenterol Hepatol (2005) 1.06
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology (2014) 1.04
Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest (2006) 1.02
The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis (2007) 1.02
Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int (2011) 0.99
Diabetes mellitus and lung function. Med Princ Pract (2003) 0.96
Legionella species colonization of water distribution systems, pools and air conditioning systems in cruise ships and ferries. BMC Public Health (2008) 0.95
Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res (2006) 0.92
The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm Med (2004) 0.92
Salmonella enteritidis Infection Complicated by Acute Myocarditis: A Case Report and Review of the Literature. Cardiol Res Pract (2011) 0.92
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol (2012) 0.92
IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol (2008) 0.91
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther (2011) 0.89
Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun (2005) 0.89
Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol (2002) 0.89
Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. Clin Diagn Lab Immunol (2005) 0.88
How we diagnose the antiphospholipid syndrome. Blood (2008) 0.88
Safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma. Hepat Mon (2013) 0.88
Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma. Hematol Oncol (2011) 0.87
Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series. Cases J (2009) 0.87
HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol (2005) 0.87
Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. Eur J Intern Med (2008) 0.86
Risk factors associated with HCV infection in semi-rural areas of central Greece. Eur J Intern Med (2007) 0.86
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int (2011) 0.86
Hepatitis B virus and intrahepatic cholangiocarcinoma. Cancer Invest (2007) 0.86
HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int (2012) 0.85
Sleep apnoea syndrome and early stage cirrhosis: a pilot study. Eur J Gastroenterol Hepatol (2006) 0.85
Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis (2010) 0.85
Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun (2005) 0.84
Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol (2002) 0.84
Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity (2013) 0.84
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis (2010) 0.82
Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int (2011) 0.82
Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol (2006) 0.82
IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta (2012) 0.82
Bortezomib downregulates MGMT expression in T98G glioblastoma cells. Cell Mol Neurobiol (2013) 0.82
Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J Hepatol (2006) 0.82
Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma. Cancer Invest (2013) 0.81
Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis (2006) 0.81
Miliary tuberculosis with no pulmonary involvement in myelodysplastic syndromes: a curable, yet rarely diagnosed, disease: case report and review of the literature. Ann Clin Microbiol Antimicrob (2008) 0.81
Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. World J Gastroenterol (2005) 0.81
Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. Eur J Gastroenterol Hepatol (2004) 0.80
Evaluation of a microsphere-based flow cytometric assay for diagnosis of celiac disease. J Immunoassay Immunochem (2004) 0.80
Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract (2008) 0.80
Leptospirosis and pancytopenia: two case reports and review of the literature. J Infect (2005) 0.79
Lack of association between appendectomy and primary biliary cirrhosis. Scand J Gastroenterol (2006) 0.78
Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol (2008) 0.78
Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis (2004) 0.78
Clinical significance of interleukin-22 in multiple myeloma. Hematology (2014) 0.78
Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol (2005) 0.78
Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.77
The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma. Tumour Biol (2012) 0.77
Prognostic impact of angiopoietin-2 in multiple myeloma. J Cancer Res Clin Oncol (2014) 0.77
Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World J Gastroenterol (2012) 0.77
Confluent hepatic fibrosis as the presenting imaging sign in nonadvanced alcoholic cirrhosis. Clin Imaging (2004) 0.76
Mast cells influence the proliferation rate of myeloma plasma cells. Cancer Invest (2015) 0.76
Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.76
Advanced intrahepatic cholangiocarcinoma in hepatitis C virus-related decompensated cirrhosis: case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 0.75
Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. Gastroenterol Res Pract (2010) 0.75
The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients. Int Arch Allergy Immunol (2016) 0.75
Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. World J Hepatol (2013) 0.75
Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features. Am J Kidney Dis (2005) 0.75
Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report. ISRN Hematol (2011) 0.75
Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma. Med Oncol (2013) 0.75
Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: a case report and review of the literature. World J Gastroenterol (2006) 0.75
Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma. Leuk Res (2013) 0.75
Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism. Int J Cardiol (2013) 0.75
Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. Eur J Intern Med (2011) 0.75
Elevated serum angiogenin in multiple myeloma. Hematol J (2003) 0.75
The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple. Pathol Oncol Res (2013) 0.75
Bone marrow findings in patients with autoimmune liver diseases. J Gastroenterol Hepatol (2008) 0.75
Kikuchi's disease: a benign cause of fever and cervical lymphadenopathy. Eur J Intern Med (2005) 0.75
Activated Protein C-Resistance Determination and Vascular Access Thrombosis in Populations with High Prevalence of Factor V Leiden. Nephron (2015) 0.75